#1 Clinical Trials Search in Europe

Cocarboxylase Tetrahydrate

Cocarboxylase Tetrahydrate, a component found in vitamin supplements, is currently being studied in clinical trials for its potential role in treating cardiogenic shock. This article explores the ongoing research into this compound’s effectiveness when used alongside other treatments for patients with severe heart conditions. We’ll examine the objectives, methods, and potential outcomes of these trials to better understand how Cocarboxylase Tetrahydrate might contribute to improving patient care in critical cardiac situations.

Table of Contents

What is Cocarboxylase Tetrahydrate?

Cocarboxylase Tetrahydrate is a medical compound that is part of a group of substances known as vitamins[1]. It is one of the active ingredients in a medication called Cernevit, which is a multivitamin preparation used in various medical settings[2]. Cocarboxylase is another name for thiamine pyrophosphate, which is the active form of vitamin B1 (thiamine) in the body.

Medical Uses

Cocarboxylase Tetrahydrate, as part of the Cernevit formulation, is primarily used in the following situations:

  • To provide vitamin supplementation for patients who cannot eat normally
  • In patients receiving parenteral nutrition (nutrition given through a vein)
  • To prevent or treat vitamin deficiencies in critically ill patients

While the specific role of Cocarboxylase Tetrahydrate is not explicitly stated in the provided clinical trial information, its presence in Cernevit suggests it plays a crucial role in maintaining proper vitamin B1 levels in the body[1][2].

Administration

Cernevit, which contains Cocarboxylase Tetrahydrate, is typically administered as follows:

  • It comes as a powder that is mixed to create a solution for injection or infusion[2]
  • The medication is usually given intravenously (directly into a vein)[2]
  • The dosage and frequency of administration are determined by healthcare professionals based on the patient’s individual needs

Ongoing Research

While the clinical trials mentioned do not specifically focus on Cocarboxylase Tetrahydrate, they provide insight into the contexts where this compound might be used:

  • The trials are investigating the use of levosimendan, another cardiac medication, in patients with cardiogenic shock (a condition where the heart suddenly can’t pump enough blood to meet the body’s needs)[1][2]
  • Patients in these trials may receive various supportive treatments, including vitamin supplementation, which could potentially involve Cernevit and its component Cocarboxylase Tetrahydrate

Potential Benefits

While not directly studied in the provided trials, Cocarboxylase Tetrahydrate, as part of vitamin B1, may offer the following benefits:

  • Support for energy metabolism in the body
  • Maintenance of proper nervous system function
  • Potential support for heart function, which could be particularly relevant in patients with cardiac conditions

Considerations and Precautions

When receiving treatment that includes Cocarboxylase Tetrahydrate (as part of Cernevit), patients should be aware of the following:

  • This medication is typically administered by healthcare professionals in a controlled setting
  • It’s important to inform your doctor about any allergies or sensitivities you may have to vitamins or other medications
  • While vitamin supplementation is generally safe, it should be done under medical supervision, especially in critically ill patients

As always, it’s crucial to discuss any questions or concerns about your treatment with your healthcare provider. They can provide personalized information based on your specific medical condition and needs.

Aspect Details
Drug Studied Cocarboxylase Tetrahydrate (as part of Cernevit vitamin supplement)
Medical Condition Cardiogenic Shock
Primary Objectives Assess efficacy in improving cardiac output, facilitating ECMO weaning, and reducing mortality
Study Design Randomized, controlled trials comparing treatment with conventional strategies
Key Endpoints Changes in cardiac function, mortality rates, ECMO weaning success, organ function preservation
Patient Eligibility Adults with cardiogenic shock, meeting specific inclusion criteria
Potential Impact Improved treatment strategies for cardiogenic shock, potentially reducing mortality and improving patient outcomes

FAQ

  • What is Cocarboxylase Tetrahydrate? Cocarboxylase Tetrahydrate is an active substance found in vitamin supplements. It is being studied as part of a combination therapy for patients with cardiogenic shock, a serious condition where the heart cannot pump enough blood to meet the body's needs.
  • How is Cocarboxylase Tetrahydrate being used in clinical trials? In the clinical trials, Cocarboxylase Tetrahydrate is one of several active substances in a vitamin supplement called Cernevit. This supplement is being used alongside other treatments for patients with cardiogenic shock, particularly those who are being weaned from extracorporeal membrane oxygenation (ECMO) support.
  • What are the main objectives of these clinical trials? The main objectives of these trials are to assess the effectiveness of treatments containing Cocarboxylase Tetrahydrate in improving cardiac function, facilitating ECMO weaning, and reducing mortality rates in patients with cardiogenic shock.
  • Who can participate in these clinical trials? Generally, adult patients (18 years or older) with cardiogenic shock who meet specific criteria related to their condition and treatment are eligible. However, there are several exclusion criteria, such as certain pre-existing conditions or previous treatments, that may disqualify some patients.
  • What are the potential benefits of this research? If successful, this research could lead to improved treatment strategies for cardiogenic shock, potentially reducing mortality rates, shortening hospital stays, and improving overall outcomes for patients with severe heart conditions.

Ongoing Clinical Trials on Cocarboxylase Tetrahydrate

  • Study on the Early Use of Levosimendan Compared to Placebo for Patients with Cardiogenic Shock

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effects of Levosimendan for Patients with Cardiogenic Shock Being Weaned from ECMO

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

Glossary

  • Cardiogenic Shock: A serious condition where the heart suddenly can't pump enough blood to meet the body's needs, often due to a severe heart attack.
  • ECMO: Extracorporeal Membrane Oxygenation, a life support machine that temporarily takes over the function of the heart and lungs.
  • Levosimendan: A medication used to treat acute heart failure by improving the heart's ability to pump blood.
  • Inotrope: A type of medication that changes the force of heart muscle contractions.
  • Dobutamine: A medication used to treat heart failure and cardiogenic shock by increasing cardiac output.
  • Norepinephrine: A medication used to treat critically low blood pressure, often in shock patients.
  • Lactate: A substance produced by the body when oxygen levels are low, often used as a marker of tissue perfusion in shock patients.
  • Morbidity: The state of being diseased or the incidence of disease in a population.
  • Mortality: The state of being subject to death or the incidence of death in a population.
  • Biomarker: A measurable substance in the body that can indicate the presence or severity of a disease or condition.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-levosimendan-for-patients-with-cardiogenic-shock-being-weaned-from-ecmo/
  2. http://clinicaltrials.eu/trial/study-on-the-early-use-of-levosimendan-compared-to-placebo-for-patients-with-cardiogenic-shock/